Meeder Asset Management’s NovoCure NVCR Stock Holding History

Meeder Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,017	Closed	-$62.8K	–	985
2024 Q3	$62.8K	Sell	4,017 -704	-15%	-$12.8K	﹤0.01%	333
2024 Q2	$80.9K	Buy	+4,721	New	+$83K	0.01%	283
2021 Q4	–	Sell	-2	Closed	–	–	1952
2021 Q3	$0	Sell	2 -1,655	-100%	-$250K	﹤0.01%	2591
2021 Q2	$368K	Buy	1,657 +382	+30%	+$74.3K	0.02%	588
2021 Q1	$168K	Buy	1,275 +1,274	+127,400%	+$202K	0.01%	775
2020 Q4	$0	Hold	1	–	–	﹤0.01%	2113
2020 Q3	$0	Buy	+1	New	+$80	﹤0.01%	2311
2020 Q2	–	Sell	-320	Closed	-$22K	–	2315
2020 Q1	$22K	Sell	320 -1,126	-78%	-$89K	﹤0.01%	1207
2019 Q4	$122K	Buy	1,446 +807	+126%	+$65.1K	0.01%	737
2019 Q3	$48K	Buy	+639	New	+$51.1K	﹤0.01%	1031
2018 Q1	–	Sell	-3	Closed	–	–	1688
2017 Q4	$0	Buy	+3	New	+$58	﹤0.01%	1754
2017 Q2	–	Sell	-382	Closed	-$3K	–	1807
2017 Q1	$3K	Hold	382	–	–	﹤0.01%	1269
2016 Q4	$3K	Buy	+382	New	+$3.07K	﹤0.01%	904

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Meeder Asset Management's NVCR Position: Q4 2024 in Review

Meeder Asset Management sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 4,017 shares — an estimated $62.8K sold.

Meeder Asset Management first reported a position in NVCR in Q4 2016 and held it in 13 quarters. The position peaked at $368K in Q2 2021. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

Meeder Asset Management reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
Meeder Asset Management sold 4,017 NovoCure shares in Q4 2024, an estimated $62.8K.
Meeder Asset Management first reported a position in NovoCure in Q4 2016 and held it in 13 quarters.
Meeder Asset Management's NovoCure position peaked at $368K in Q2 2021.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on Meeder Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.